Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Embecta is in an intricate phase as strategists contemplate its potential as an acquisition target.</li><li>Analyzing Embecta's scenario involves balancing an array of factors highlighted during its thorough earnings discussion.</li><li>On the positive side, Embecta has displayed a robust earnings performance in the fiscal second quarter of 2024, with a total revenue growth of 3.6% on an as-reported basis and 4.5% on a constant currency basis.</li></ul>

Embecta is in an intricate phase as strategists contemplate its potential as an acquisition target.Analyzing Embecta's scenario involves balancing an array of factors highlighted during its thorough earnings discussion.On the positive side, Embecta has displayed a robust earnings performance in the fiscal second quarter of 2024, with a total revenue growth of 3.6% on an as-reported basis and 4.5% on a constant currency basis.

Embecta Corp Exploring A Potential Sale! Is This The Much Needed Move For A Potential Turnaround? - Financial Forecasts

United States

Embecta Corp. provides medical supplies and equipment. The Company offers diabetes medication monitoring and delivery equipment. Embecta serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Embecta (EMBC US)

Embecta Corp Exploring A Potential Sale! Is This The Much Needed Move For A Potential Turnaround? - Financial Forecasts

Embecta is in an intricate phase as strategists contemplate its potential as an acquisition target. Analyzing Embecta's scenario involves...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)